Report
Charles Pinel
EUR 500.00 For Business Accounts Only

Cellectis 25 juin 2019

Comme lors de l'exercice précédent, Proxinvest regrette que la société maintienne la possibilité de l'usage des autorisations d'augmentation du capital en période d'offre publique, ce qui nous conduit à recommander l'opposition aux résolutions 10 à 12, 14 et 15. Par ailleurs, les montants proposés dans ces résolutions ainsi que dans les résolutions 19 à 23 sont excessifs.

Proxinvest regrette également le manque de communication concernant les rémunérations des dirigeants. De plus, la société empêche les actionnaires de se prononcer sur la rémunération en ne soumettant pas au vote de résolution à ce sujet.

Il est à noter que la société ne respecte le taux de féminisation définie par la loi Copé-Zimmermann. En effet la société possède un taux de féminisation de 13%. La société n'est pas soumise à cette loi puisque la société évolue sur le marché d'Euronext Growth.

Underlying
Cellectis

Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.

Provider
Proxinvest
Proxinvest

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Analysts
Charles Pinel

Other Reports on these Companies
Other Reports from Proxinvest
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch